Your download is now in progress and you may close this window

Did you know that with a free Taylor & Francis Online account you can gain access to the following benefits?

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Have an account?
Login now Don't have an account?
Register for free

Login or register to access this feature

Have an account?
Login now Don't have an account?
Register for free

Choose new content alerts to be informed about new research of interest to you
Easy remote access to your institution's subscriptions on any device, from any location
Save your searches and schedule alerts to send you new results
Export your search results into a .csv file to support your research

Search in:

Advanced search

Journal of Medical Economics Volume 27, 2024 - Issue 1

Submit an article Journal homepage

Open access

574

Views

CrossRef citations to date

Altmetric

Oncology

Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placebo

Siguroli Teitssona Bristol Myers Squibb, Uxbridge, UKCorrespondence[email protected]

https://orcid.org/0009-0001-7378-1675

Thor-Henrik Brodtkorbb RTI Health Solutions, Ljungskile, Sweden

https://orcid.org/0000-0002-9899-233X

Murat Kurtc Bristol Myers Squibb, Princeton, NJ, USA

Miraj Y. Patelc Bristol Myers Squibb, Princeton, NJ, USA

https://orcid.org/0000-0002-3543-1420

Tayla Porettac Bristol Myers Squibb, Princeton, NJ, USA

Christopher Knightd RTI Health Solutions, Manchester, UK

Farzam Kamgarb RTI Health Solutions, Ljungskile, Sweden

Stephen Palmere Centre for Health Economics, University of York, York, UK

https://orcid.org/0000-0002-7268-2560

show all

Pages 473-481 | Received 21 Dec 2023, Accepted 14 Feb 2024, Published online: 25 Mar 2024

Cite this article
https://doi.org/10.1080/13696998.2024.2322394
CrossMark

Full Article
Figures & data
References
Supplemental
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF View EPUB EPUB

Citations (1)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Thor-Henrik Brodtkorb, Christopher Knight, Farzam Kamgar, Siguroli Teitsson, Murat Kurt, Miraj Y. Patel, Tayla Poretta, Ronac Mamtani & Stephen Palmer. Cost-effectiveness of nivolumab versus surveillance for the adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence: a US payer perspective. Journal of Medical Economics 0:0, pages 1-34.
Read now

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references